Charles AC, Digre KB, Goadsby PJ, Robbins MS, Hershey A; American Headache Society. Calcitonin gene-related peptide-targeting therapies are a first-line option for the prevention of migraine: an American Headache Society position statement update. Headache. 2024;64(4):333-341. doi:10.1111/head.14692

Ishii R, Schwedt TJ, Dumkrieger G, et al. Chronic versus episodic migraine: the 15-day threshold does not adequately reflect substantial differences in disability across the full spectrum of headache frequency. Headache. 2021;61(7):992-1003. doi:10.1111/head.14154

Pozo-Rosich P, Caronna E, Sacco S, et al. Early treatment in migraine – a call to shift prevention from attacks to disease progression: a position statement from the International Headache Society. Cephalalgia. 2025;45(10):3331024251387721. doi:10.1177/03331024251387721

Sacco S, Ashina M, Diener HC, et al. Setting higher standards for migraine prevention: a position statement of the International Headache Society. Cephalalgia. 2025;45(2):3331024251320608. doi:10.1177/03331024251320608

Sacco S, Braschinsky M, Ducros A, et al. European Headache Federation consensus on the definition of resistant and refractory migraine: developed with the endorsement of the European Migraine & Headache Alliance (EMHA). J Headache Pain. 2020;21(1):76. doi:10.1186/s10194-020-01130-5

Serrano D, Lipton RB, Scher AI, et al. Fluctuations in episodic and chronic migraine status over the course of 1 year: implications for diagnosis, treatment and clinical trial design. J Headache Pain. 2017;18(1):101. doi:10.1186/s10194-017-0787-1